Document is current
Any future updates will be listed below
-
Authors
Harachi, Mio
Masui, Kenta http://orcid.org/0000-0002-5824-6690
Shimizu, Erika
Murakami, Kumiko
Onizuka, Hiromi
Muragaki, Yoshihiro
Kawamata, Takakazu
Nakayama, Hisako
Miyata, Mariko
Komori, Takashi
Cavenee, Webster K.
Mischel, Paul S.
Kurata, Atsushi
Shibata, Noriyuki
-
Funding
Funding for this research was provided by:
Takeda Science Foundation
Japan Society for the Promotion of Science (JP23K06487)
National Institutes of Health (U24CA264379, RO1 CA238249)
National Brain Tumor Society
- License Information
-
More Information
Article History
Received: 29 September 2023
Accepted: 25 February 2024
First Online: 13 March 2024
Declarations
:
: All methods and experimental protocols related to human subjects were approved by each institutional review board of Ethics Committee. The procedures related to human subjects were carried out in accordance with each institutional review board-approved protocol and Declaration of Helsinki, 2013. Surgical cases of human gliomas were a part of the collections from Tokyo Women’s Medical University Hospital, and physicians obtained informed consent from the patients.
: Not applicable.
: PSM is a co-founder of Boundless Bio, Inc. He has equity in the company and chairs the scientific advisory board, for which he is compensated. PSM is also a consultant for Sage Therapeutics, Asteroid Therapeutics, and Autobahn Therapeutics, and scientific co-founder and consultant for Pretzel Therapeutics, Inc. WKC is co-founder of Interleukin Combinatorial Therapeutic, Inc., InVaMet, Inc., and io9, LLC. None of these companies provided direct support for the studies described here.
